Investigational Drug Information for Apaziquone
✉ Email this page to a colleague
What is the drug development status for Apaziquone?
Apaziquone is an investigational drug.
There have been 9 clinical trials for Apaziquone.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 9th 2015.
The most common disease conditions in clinical trials are Urinary Bladder Neoplasms and [disabled in preview]. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Handok Inc., and Handok Pharmaceuticals Co., Ltd.
There are three hundred and sixty-four US patents protecting this investigational drug and four international patents.
Summary for Apaziquone
| US Patents | 364 |
| International Patents | 4,983 |
| US Patent Applications | 856 |
| WIPO Patent Applications | 600 |
| Japanese Patent Applications | 58 |
| Clinical Trial Progress | Phase 3 (2015-10-09) |
| Vendors | 36 |
Recent Clinical Trials for Apaziquone
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 |
| A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | Allergan | Phase 3 |
Clinical Trial Summary for Apaziquone
Top disease conditions for Apaziquone
Top clinical trial sponsors for Apaziquone
US Patents for Apaziquone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Apaziquone | ⤷ Try a Trial | Formulations for tailored drug release | South Dakota Board of Regents (Pierre, SD) Sanford Health (Sioux Falls, SD) | ⤷ Try a Trial |
| Apaziquone | ⤷ Try a Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Try a Trial |
| Apaziquone | ⤷ Try a Trial | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Try a Trial |
| Apaziquone | ⤷ Try a Trial | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | ⤷ Try a Trial |
| Apaziquone | ⤷ Try a Trial | Method of targeting glycoproteins to treat cancer | Board of Regents of the University of Nebraska (Lincoln, NE) | ⤷ Try a Trial |
| Apaziquone | ⤷ Try a Trial | Heteroaryl compounds as IRAK inhibitors and uses thereof | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Apaziquone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Apaziquone | World Intellectual Property Organization (WIPO) | WO2016065255 | 2034-10-23 | ⤷ Try a Trial |
| Apaziquone | Canada | CA2922341 | 2033-08-28 | ⤷ Try a Trial |
| Apaziquone | European Patent Office | EP3038618 | 2033-08-28 | ⤷ Try a Trial |
| Apaziquone | World Intellectual Property Organization (WIPO) | WO2015031608 | 2033-08-28 | ⤷ Try a Trial |
| Apaziquone | World Intellectual Property Organization (WIPO) | WO2016049568 | 2034-09-25 | ⤷ Try a Trial |
| Apaziquone | China | CN108368161 | 2035-09-10 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
